Commentaries
Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the
Wednesday, August 31, 2022
